To those of you who have family members with Fragile X, thank you for being interested in clinical trials! This is a challenging phase for all of us, and as exciting as it is, we know many of you have questions about what it means to be in a clinical trial.
Each study is supervised by a doctor that specializes in Fragile X. These trials are free, you do not have to tell your insurance company, and you can leave any time you want. Travel costs are usually covered.
The FDA requires two successful large-scale clinical trials before it will consider approving a new treatment. If studies are successful and the FDA approves new drugs, others with Fragile X can also have access to these medicines.
Studies Currently Accepting Participants
Please visit clinicaltrials.gov for a complete listing of Fragile X syndrome clinical trials.
- 2016-18: Combining Lovastatin and Minocycline – Quebec, Canada – Positive results reported
- 2012-15: Epigallocatechin gallate (mega green tea extract) – Mara Dierssen – Barcelona, Spain.
- 2016 – Double Blind Crossover Trial of Ganaxolone – Frank Kooy and Anke Van Dijck- Antwerp, Belgium, sponsored by FRAXA Research Foundation. Dr. Randi Hagerman conducted a part of this trial in Davis, CA, sponsored by Marinus Pharmaceuticals.
“Consistent with the mechanism of action and preclinical studies, anxious FXS patients treated with ganaxolone showed clinically relevant reductions in anxiety across several scales and subscales sensitive to measuring changes in anxious behavior. These results are encouraging and suggest that ganaxolone may improve anxiety in children with FXS, which could potentially allow them, as well as their families, to experience a more stabilized lifestyle.” – Frank Kooy, PhD.
- 2015 – Neuren’s trofinetide showed some success in small Phase 2 clinical trials in Fragile X syndrome and in Rett Syndrome
- 2012-13: Open-Label Pilot Trial of Lovastatin – Francois Corbin, MD, PhD — Sherbrooke, Canada
- 2008: Minocycline trial – Carlo Paribello, MD – Toronto, Canada. Positive results were published
- a pilot lithium trial — Elizabeth Berry-Kravis, MD, PhD, and funded by FRAXA. Positive results were published
- pilot trial of CX516 — Elizabeth Berry-Kravis, and funded by FRAXA.
- Phase III trials of arbaclofen were completed by Seaside Therapeutics but results were disappointing in both Fragile X and autism. However, baclofen is an available drug.